Key Points
-
Elderly (aged ≥70 years) patients with prostate cancer constitute a unique patient population
-
On the one hand, elderly patients are often denied effective treatments because of fear of toxicity or diminished efficacy merely based on their age
-
On the other hand, elderly patients can be unduly subjected to intense therapies despite multiple comorbidities in the setting of indolent disease
-
It is important to individualize therapy based on the comorbidities, functional status, nutritional status and aggressiveness of disease rather than age alone
Abstract
The incidence of prostate cancer increases with age. Current evidence suggests that prostate cancer is under treated in patients aged ≥70 years, despite evidence of efficacy and acceptable toxicity. Radical cystectomy and definitive radiotherapy are often denied owing to fears of post-operative complications and radiotherapy-associated gastrointestinal and genitourinary toxicity. However, modern radical prostatectomy techniques provide excellent clinical outcomes with low perioperative morbidity. Moreover, volume-restricted intensity-modulated radiation therapy is a significant improvement over previous 2D conformal radiotherapy with similar efficacy and lower toxicity. Androgen-deprivation therapy is also under-prescribed among the elderly, owing to concerns of increases in cardiac deaths and osteoporosis acceleration. However, prospective trials have not identified any increase in cardiovascular mortality among elderly men receiving androgen-deprivation therapy compared to age-matched controls. Most patients on androgen deprivation eventually progress to a castration-resistant state. At this stage, the disease still responds to newer agents that target the androgen pathway and to chemotherapy. Among the elderly, chemotherapy is under-prescribed even though it has been demonstrated to be palliative and improve survival. We describe the trends in prostate cancer management in the elderly and the importance of assessing comorbidity status, tumour characteristics, and health status, including a complete geriatric evaluation, before making treatment recommendations.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Jemal, A. et al. Global cancer statistics. CA Cancer J. Clin. 61, 69–90 (2011).
Soos, G. et al. The prevalence of prostate carcinoma and its precursor in Hungary: an autopsy study. Eur. Urol. 48, 739–744 (2005).
Carter, H. B. et al. Early detection of prostate cancer: AUA Guideline. J. Urol. 190, 419–426 (2013).
Howlader, N. et al. SEER Cancer Statistics Review, 1975–2010 [online], (2013).
Pound, C. R. et al. Natural history of progression after PSA elevation following radical prostatectomy. JAMA 281, 1591–1597 (1999).
Scosyrev, E., Messing, E. M., Mohile, S., Golijanin, D. & Wu, G. Prostate cancer in the elderly: frequency of advanced disease at presentation and disease-specific mortality. Cancer 118, 3062–3070 (2012).
D'Amico, A. V. et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 280, 969–974 (1998).
Thompson, I. et al. Guideline for the management of clinically localized prostate cancer: 2007 update. J. Urol. 177, 2106–2131 (2007).
Walz, J. et al. Clinicians are poor raters of life-expectancy before radical prostatectomy or definitive radiotherapy for localized prostate cancer. BJU Int. 100, 1254–1258 (2007).
Leung, K. M., Hopman, W. M. & Kawakami, J. Challenging the 10-year rule: the accuracy of patient life expectancy predictions by physicians in relation to prostate cancer management. Can. Urol. Assoc. J. 6, 367–373 (2012).
Chow, E. et al. Accuracy of survival prediction by palliative radiation oncologists. Int. J. Radiat. Oncol. Biol. Phys. 61, 870–873 (2005).
Jeldres, C. Life expectancy estimation in prostate cancer patients. Can. Urol. Assoc. J. 6, 374–375 (2012).
Walz, J. et al. A nomogram predicting 10-year life expectancy in candidates for radical prostatectomy or radiotherapy for prostate cancer. J. Clin. Oncol. 25, 3576–3581 (2007).
Mohile, S. G., Lachs, M. & Dale, W. Management of prostate cancer in the older man. Semin. Oncol. 35, 597–617 (2008).
Faivre, J., Lemmens, V. E., Quipourt, V. & Bouvier, A. M. Management and survival of colorectal cancer in the elderly in population-based studies. Eur. J. Cancer 43, 2279–2284 (2007).
Han, M. In Campbell-Walsh Urology 10th edn Ch. 94 (eds Wein, A. J. et al.) 2801–2829 (Elsevier Saunders, 2012).
Begg, C. B. et al. Variations in morbidity after radical prostatectomy. N. Engl. J. Med. 346, 1138–1144 (2002).
Ploussard, G. et al. Challenging treatment decision-making in older urologic cancer patients. World J. Urol. 32, 299–308 (2014).
Thompson, R. H., Slezak, J. M., Webster, W. S. & Lieber, M. M. Radical prostatectomy for octogenarians: how old is too old? Urology 68, 1042–1045 (2006).
Sanchez-Salas, R. et al. Laparoscopic radical prostatectomy is feasible and effective in 'fit' senior men with localized prostate cancer. BJU Int. 106, 1530–1536 (2010).
Siddiqui, S. A. et al. Impact of patient age at treatment on outcome following radical retropubic prostatectomy for prostate cancer. J. Urol. 175, 952–957 (2006).
Loeb, S. et al. Progression after radical prostatectomy for men in their thirties compared to older men. BJU Int. 101, 1503–1506 (2008).
Heidenreich, A. et al. EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease. Eur. Urol. 59, 61–71 (2011).
Droz, J. P. et al. Background for the proposal of SIOG guidelines for the management of prostate cancer in senior adults. Crit. Rev. Oncol. Hematol. 73, 68–91 (2010).
Walz, J. et al. Accuracy of life tables in predicting overall survival in patients after radical prostatectomy. BJU Int. 102, 33–38 (2008).
Heinzer, H. & Steuber, T. Prostate cancer in the elderly. Urol. Oncol. 27, 668–672 (2009).
Schwartz, K. L., Alibhai, S. M., Tomlinson, G., Naglie, G. & Krahn, M. D. Continued undertreatment of older men with localized prostate cancer. Urology 62, 860–865 (2003).
Albertsen, P. C., Hanley, J. A. & Fine, J. 20-year outcomes following conservative management of clinically localized prostate cancer. JAMA 293, 2095–2101 (2005).
Konety, B. R., Cowan, J. E. & Carroll, P. R. Patterns of primary and secondary therapy for prostate cancer in elderly men: analysis of data from CaPSURE. J. Urol. 179, 1797–1803 (2008).
Droz, J. P. et al. Management of prostate cancer in older men: recommendations of a working group of the International Society of Geriatric Oncology. BJU Int. 106, 462–469 (2010).
Fitzpatrick, J. M., Graefen, M., Payne, H. A., Scotte, F. & Aapro, M. S. A comment on the International Society of Geriatric Oncology guidelines: evidence-based advice for the clinical setting. Oncologist 17 (Suppl. 1), 31–35 (2012).
Cooperberg, M. R., Broering, J. M. & Carroll, P. R. Time trends and local variation in primary treatment of localized prostate cancer. J. Clin. Oncol. 28, 1117–1123 (2010).
Abdollah, F. et al. Competing-risks mortality after radiotherapy vs observation for localized prostate cancer: a population-based study. Int. J. Radiat. Oncol. Biol. Phys. 84, 95–103 (2012).
Pilepich, M. V. et al. Phase III radiation therapy oncology group (RTOG) trial 86–10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate. Int. J. Radiat. Oncol. Biol. Phys. 50, 1243–1252 (2001).
Bolla, M. et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. Lancet 360, 103–106 (2002).
Fiorica, F. et al. Safety and efficacy of radiotherapy treatment in elderly patients with localized prostate cancer: a retrospective analysis. Arch. Gerontol. Geriatr. 51, 277–282 (2010).
Nanda, A. et al. Predictors of prostate cancer-specific mortality in elderly men with intermediate-risk prostate cancer treated with brachytherapy with or without external beam radiation therapy. Int. J. Radiat. Oncol. Biol. Phys. 77, 147–152 (2010).
Jani, A. B. & Gratzle, J. Analysis of impact of age and race on biochemical control after radiotherapy in different prostate cancer settings. Urology 66, 124–129 (2005).
Geinitz, H. et al. 3D conformal radiation therapy for prostate cancer in elderly patients. Radiother. Oncol. 76, 27–34 (2005).
Jani, A. B., Parikh, S. D., Vijayakumar, S. & Gratzle, J. Analysis of influence of age on acute and chronic radiotherapy toxicity in treatment of prostate cancer. Urology 65, 1157–1162 (2005).
Villa, S., Bedini, N., Fallai, C. & Olmi, P. External beam radiotherapy in elderly patients with clinically localized prostate adenocarcinoma: age is not a problem. Crit. Rev. Oncol. Haematol. 48, 215–225 (2003).
Schultheiss, T. E., Hanks, G. E., Hunt, M. A. & Lee, W. R. Incidence of and factors related to late complications in conformal and conventional radiation treatment of cancer of the prostate. Int. J. Radiat. Oncol. Biol. Phys. 32, 643–649 (1995).
Skwarchuk, M. W. et al. Late rectal toxicity after conformal radiotherapy of prostate cancer (I): multivariate analysis and dose-response. Int. J. Radiat. Oncol. Biol. Phys. 47, 103–113 (2000).
Merrick, G. S. et al. Prostate brachytherapy in men > or =75 years of age. Int. J. Radiat. Oncol. Biol. Phys. 72, 415–420 (2008).
D'Amico, A. V., Chen, M. H., Renshaw, A. A., Loffredo, M. & Kantoff, P. W. Androgen suppression and radiation vs radiation alone for prostate cancer: a randomized trial. JAMA 299, 289–295 (2008).
Hoffman, K. E. et al. Prostate cancer-specific mortality and the extent of therapy in healthy elderly men with high-risk prostate cancer. Cancer 116, 2590–2595 (2010).
Nanda, A., Chen, M. H., Braccioforte, M. H., Moran, B. J. & D'Amico, A. V. Hormonal therapy use for prostate cancer and mortality in men with coronary artery disease-induced congestive heart failure or myocardial infarction. JAMA 302, 866–873 (2009).
Herman, M. G. et al. Technical aspects of daily online positioning of the prostate for three-dimensional conformal radiotherapy using an electronic portal imaging device. Int. J. Radiat. Oncol. Biol. Phys. 57, 1131–1140 (2003).
Zelefsky, M. J. et al. High dose radiation delivered by intensity modulated conformal radiotherapy improves the outcome of localized prostate cancer. J. Urol. 166, 876–881 (2001).
Leibel, S. A. et al. Technological advances in external-beam radiation therapy for the treatment of localized prostate cancer. Semin. Oncol. 30, 596–615 (2003).
Bekelman, J. E. et al. Outcomes after intensity-modulated versus conformal radiotherapy in older men with nonmetastatic prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. 81, e325–e334 (2011).
Dearnaley, D. P. et al. Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomised controlled trial. Lancet Oncol. 8, 475–487 (2007).
Peeters, S. T. et al. Dose-response in radiotherapy for localized prostate cancer: results of the Dutch multicentre randomized phase III trial comparing 68 Gy of radiotherapy with 78 Gy. J. Clin. Oncol. 24, 1990–1996 (2006).
Zietman, A. L. et al. Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: a randomized controlled trial. JAMA 294, 1233–1239 (2005).
Zelefsky, M. J. et al. Incidence of late rectal and urinary toxicities after three-dimensional conformal radiotherapy and intensity-modulated radiotherapy for localized prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. 70, 1124–1129 (2008).
Huggins, C. H. C. Studies on Prostatic Cancer I. The effect of castration, of oestrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res. 1, 293–297 (1941).
Sharifi, N., Gulley, J. L. & Dahut, W. L. Androgen deprivation therapy for prostate cancer. JAMA 294, 238–244 (2005).
Scher, H. I., Morris, M. J., Basch, E. & Heller, G. End points and outcomes in castration-resistant prostate cancer: from clinical trials to clinical practice. J. Clin. Oncol. 29, 3695–3704 (2011).
Gomella, L. G. Effective testosterone suppression for prostate cancer: is there a best castration therapy? Rev. Urol. 11, 52–60 (2009).
Cassileth, B. R. et al. Patients' choice of treatment in stage D prostate cancer. Urology 33, 57–62 (1989).
Lin, B. J., Chen, K. K., Chen, M. T. & Chang, L. S. The time for serum testosterone to reach castrate level after bilateral orchiectomy or oral oestrogen in the management of metastatic prostatic cancer. Urology 43, 834–837 (1994).
Kintzel, P. E., Chase, S. L., Schultz, L. M. & O'Rourke, T. J. Increased risk of metabolic syndrome, diabetes mellitus, and cardiovascular disease in men receiving androgen deprivation therapy for prostate cancer. Pharmacotherapy 28, 1511–1522 (2008).
Shahinian, V. B., Kuo, Y. F., Freeman, J. L. & Goodwin, J. S. Risk of the “androgen deprivation syndrome” in men receiving androgen deprivation for prostate cancer. Arch. Intern. Med. 166, 465–471 (2006).
Shahinian, V. B., Kuo, Y. F., Freeman, J. L. & Goodwin, J. S. Risk of fracture after androgen deprivation for prostate cancer. N. Engl. J. Med. 352, 154–164 (2005).
Tsai, H. K., D'Amico, A. V., Sadetsky, N., Chen, M. H. & Carroll, P. R. Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality. J. Natl Cancer Inst. 99, 1516–1524 (2007).
Ketchandji, M., Kuo, Y. F., Shahinian, V. B. & Goodwin, J. S. Cause of death in older men after the diagnosis of prostate cancer. J. Am. Geriatr. Soc. 57, 24–30 (2009).
Keating, N. L., O'Malley, A. J. & Smith, M. R. Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J. Clin. Oncol. 24, 4448–4456 (2006).
D'Amico, A. V. et al. Influence of androgen suppression therapy for prostate cancer on the frequency and timing of fatal myocardial infarctions. J. Clin. Oncol. 25, 2420–2425 (2007).
Efstathiou, J. A. et al. Cardiovascular mortality and duration of androgen deprivation for locally advanced prostate cancer: analysis of RTOG 92–02. Eur. Urol. 54, 816–823 (2008).
Nguyen, P. L. et al. Association of androgen deprivation therapy with cardiovascular death in patients with prostate cancer: a meta-analysis of randomized trials. JAMA 306, 2359–2366 (2011).
Smith, M. R., Klotz, L., van der Meulen, E., Colli, E. & Tanko, L. B. Gonadotropin-releasing hormone blockers and cardiovascular disease risk: analysis of prospective clinical trials of degarelix. J. Urol. 186, 1835–1842 (2011).
Saad, F. et al. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J. Natl Cancer Inst. 94, 1458–1468 (2002).
Serpa Neto, A. et al. Bisphosphonate therapy in patients under androgen deprivation therapy for prostate cancer: a systematic review and meta-analysis. Prostate Cancer Prostatic Dis. 15, 36–44 (2012).
Fizazi, K. et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet 377, 813–822 (2011).
Smith, M. R. et al. Denosumab and bone metastasis-free survival in men with nonmetastatic castration-resistant prostate cancer: exploratory analyses by baseline prostate-specific antigen doubling time. J. Clin. Oncol. 31, 3800–3806 (2013).
Mohile, S. G. et al. A pilot study of the vulnerable elders survey-13 compared with the comprehensive geriatric assessment for identifying disability in older patients with prostate cancer who receive androgen ablation. Cancer 109, 802–810 (2007).
Dale, W. “Staging the aging” when considering androgen deprivation therapy for older men with prostate cancer. J. Clin. Oncol. 27, 3420–3422 (2009).
Sajid, S., Mohile, S. G., Szmulewitz, R., Posadas, E. & Dale, W. Individualized decision-making for older men with prostate cancer: balancing cancer control with treatment consequences across the clinical spectrum. Semin. Oncol. 38, 309–325 (2011).
Loblaw, D. A. et al. Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an American Society of Clinical Oncology practice guideline. J. Clin. Oncol. 25, 1596–1605 (2007).
Crook, J. M., Szumacher, E., Malone, S., Huan, S. & Segal, R. Intermittent androgen suppression in the management of prostate cancer. Urology 53, 530–534 (1999).
Crook, J. M. et al. Intermittent androgen suppression for rising PSA level after radiotherapy. N. Engl. J. Med. 367, 895–903 (2012).
Hussain, M. et al. Intermittent versus continuous androgen deprivation in prostate cancer. N. Engl. J. Med. 368, 1314–1325 (2013).
Seidenfeld, J. et al. Single-therapy androgen suppression in men with advanced prostate cancer: a systematic review and meta-analysis. Ann. Intern. Med. 132, 566–577 (2000).
Cora, N. et al. Outcomes in elderly patients with metastatic castration-resistant prostate cancer (mCRPC) treated with the androgen receptor inhibitor enzalutamide: results from the phase III AFFIRM trial [abstract]. J. Clin. Oncol. 31 (Suppl. 6), a16 (2013).
Scher, H. I. et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N. Engl. J. Med. 367, 1187–1197 (2012).
Beer, T. M. et al. Enzalutamide in men with chemotherapy-naive metastatic prostate cancer (mCRPC): results of phase III PREVAIL study [abstract]. J. Clin. Oncol. 32 (Suppl. 4), aLBA1 (2014).
Small, E. J. et al. Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: a phase III trial (CALGB 9583). J. Clin. Oncol. 22, 1025–1033 (2004).
de Bono, J. S. et al. Abiraterone and increased survival in metastatic prostate cancer. N. Engl. J. Med. 364, 1995–2005 (2011).
Ryan, C. J. et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. N. Engl. J. Med. 368, 138–148 (2013).
Woodard, S. et al. Older women with breast carcinoma are less likely to receive adjuvant chemotherapy: evidence of possible age bias? Cancer 98, 1141–1149 (2003).
Bouchardy, C., Rapiti, E., Blagojevic, S., Vlastos, A. T. & Vlastos, G. Older female cancer patients: importance, causes, and consequences of undertreatment. J. Clin. Oncol. 25, 1858–1869 (2007).
Sanoff, H. K. & Goldberg, R. M. Colorectal cancer treatment in older patients. Gastrointest. Cancer Res. 1, 248–253 (2007).
Oh, W. K., Tully, P., Kantoff, P. W. & Regan, M. M. Physician attitudes toward cytotoxic chemotherapy use in patients with advanced prostate carcinoma. Cancer 97, 2171–2179 (2003).
Hurria, A. & Lichtman, S. M. Pharmacokinetics of chemotherapy in the older patient. Cancer Control 14, 32–43 (2007).
Beer, T. M., Berry, W., Wersinger, E. M. & Bland, L. B. Weekly docetaxel in elderly patients with prostate cancer: efficacy and toxicity in patients at least 70 years of age compared with patients younger than 70 years. Clin. Prostate Cancer 2, 167–172 (2003).
Extermann, M. et al. Are older French patients as willing as older American patients to undertake chemotherapy? J. Clin. Oncol. 21, 3214–3219 (2003).
Halabi, S., Vogelzang, N. J., Ou, S. S., Kelly, W. K. & Small, E. J. Clinical outcomes by age in men with hormone refractory prostate cancer: a pooled analysis of 8 Cancer and Leukemia Group B (CALGB) studies. J. Urol. 176, 81–86 (2006).
Halabi, S. et al. Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer. J. Clin. Oncol. 21, 1232–1237 (2003).
Humphreys, M. R., Fernandes, K. A. & Sridhar, S. S. Impact of age at diagnosis on outcomes in men with castrate-resistant prostate cancer (CRPC). J. Cancer 4, 304–314 (2013).
Tannock, I. F. et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N. Engl. J. Med. 351, 1502–1512 (2004).
Berthold, D. R. et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. J. Clin. Oncol. 26, 242–245 (2008).
Italiano, A. et al. Docetaxel-based chemotherapy in elderly patients (age 75 and older) with castration-resistant prostate cancer. Eur. Urol. 55, 1368–1375 (2009).
De Bono, J. S. et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 376, 1147–1154 (2010).
Heidenreich, A. et al. Safety of cabazitaxel in senior adults with metastatic castration-resistant prostate cancer: Results of the European compassionate-use programme. Eur. J. Cancer 6, 1090–1099 (2014).
US National library of medicine. ClinicaTrials.gov [online], (2013).
Cheever, M. A. & Higano, C. S. PROVENGE (Sipuleucel-T) in prostate cancer: the first FDA-approved therapeutic cancer vaccine. Clin. Cancer Res. 17, 3520–3526 (2011).
Higano, C. S. et al. Sipuleucel-T. Nat. Rev. Drug Discov. 9, 513–514 (2010).
Kantoff, P. W. et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N. Engl. J. Med. 363, 411–422 (2010).
Higano, C. S. et al. Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer. Cancer 115, 3670–3679 (2009).
Kantoff, P. W. et al. Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer. J. Clin. Oncol. 28, 1099–1105 (2010).
Cha, E. & Fong, L. Immunotherapy for prostate cancer: biology and therapeutic approaches. J. Clin. Oncol. 29, 3677–3685 (2011).
Yong, C., Onukwugha, E. & Mullins, C. D. Clinical and economic burden of bone metastasis and skeletal-related events in prostate cancer. Curr. Opin. Oncol. 3, 274–283 (2014).
Henriksen, G., Fisher, D. R., Roeske, J. C., Bruland, O. S. & Larsen, R. H. Targeting of osseous sites with alpha-emitting 223Ra: comparison with the beta-emitter 89 Sr in mice. J. Nucl. Med. 44, 252–259 (2003).
Bruland, O. S., Nilsson, S., Fisher, D. R. & Larsen, R. H. High-linear energy transfer irradiation targeted to skeletal metastases by the alpha-emitter 223Ra: adjuvant or alternative to conventional modalities? Clin. Cancer Res. 12, 6250s–6257s (2006).
Sgouros, G. et al. MIRD Pamphlet no. 22 (abridged): radiobiology and dosimetry of alpha-particle emitters for targeted radionuclide therapy. J. Nucl. Med. 51, 311–328 (2010).
Parker, C. et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N. Engl. J. Med. 369, 213–223 (2013).
Author information
Authors and Affiliations
Contributions
G.G.J. substantially contributed to discussion of content, wrote, reviewed and edited the manuscript before submission. V.A. researched data for the article, and made a substantial contribution to writing, reviewing and editing the manuscript before submission. A.S. researched data and contributed to writing the manuscript. B.R.K. substantially contributed to discussion of content, reviewed and edited the manuscript before submission.
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
PowerPoint slides
Rights and permissions
About this article
Cite this article
Jha, G., Anand, V., Soubra, A. et al. Challenges of managing elderly men with prostate cancer. Nat Rev Clin Oncol 11, 354–364 (2014). https://doi.org/10.1038/nrclinonc.2014.71
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrclinonc.2014.71
This article is cited by
-
Uroonkologische Eingriffe bei geriatrischen Patienten
Uro-News (2024)